Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 77 out of 100. Clinical trials

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

This is the pivotal Phase 3 trial for donanemab in 1,736 people with early symptomatic Alzheimer's. Donanemab slowed decline on a combined cognitive/functional scale (iADRS) by about 22-35% relative to placebo over 76 weeks, depending on tau levels at baseline. Brain swelling (ARIA-E) occurred in 24% of donanemab patients vs 2.1% on placebo, and small brain bleeds (ARIA-H) in 31.4% vs 13.6%; three deaths in the donanemab group were considered treatment-related.

What this study adds

Evidence grade: Moderate

The record lists 1,736 participants. In the Phase 3 TRAILBLAZER-ALZ 2 trial, donanemab slowed decline on a combined cognitive/functional scale by about 22-35% relative to placebo over 76 weeks, depending on baseline tau levels. Reported effect size: iADRS decline slowed by 35.1% (low/medium-tau participants) and 22.3% (combined population) vs. placebo.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Sims, JR., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., et al. (2023). Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2023.13239

Vancouver

Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023. doi:10.1001/jama.2023.13239. PMID: 37459141.

BibTeX

@article{sims2023-9857475c,
  author  = {Sims, JR. and Zimmer, J. A. and Evans, C. D. and Lu, M. and Ardayfio, P. and Sparks, J. and Wessels, A. M. and Shcherbinin, S. and Wang, H. and Monkul Nery, E. S. and Collins, E. C. and Solomon, P. and Salloway, S. and Apostolova, L. G. and Hansson, O. and Ritchie, C. and Brooks, D. A. and Mintun, M. and Skovronsky, D. M. and {TRAILBLAZER-ALZ 2 Investigators}},
  title   = {{Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial}},
  journal = {JAMA},
  year    = {2023},
  doi     = {10.1001/jama.2023.13239},
  pmid    = {37459141},
  url     = {https://doi.org/10.1001/jama.2023.13239}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 20 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

In the Phase 3 TRAILBLAZER-ALZ 2 trial, donanemab slowed decline on a combined cognitive/functional scale by about 22-35% relative to placebo over 76 weeks, depending on baseline tau levels. Brain swelling occurred in 24% of donanemab patients versus 2.1% on placebo, and three deaths in the donanemab group were considered treatment-related.

Study details

Limitations

ARIA-E in 24.0% vs. 2.1% placebo, ARIA-H in 31.4% vs. 13.6%; 3 donanemab-group deaths judged treatment-related; population pre-selected for confirmed amyloid and intermediate/high tau, limiting generalizability.

How this study scored 77/100
How this study's score is builtJournal tier 10 of 10; Journal's citation record left out, no data; Study design 11 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 3 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 1 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here 0 of 6; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multicenter collaboration left out, no data; Indexed in PubMed 2 of 2; Free to read left out, no data. 48 of the 62 points it could be judged on, which is 77 of 100. Total 77 of 100.48 of the 62 points we could judge = 77 of 100

Published in a top-tier journal, and it is a large phase 3 trial. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 48 of the 62 points we could judge it on, which is 77 out of 100.

ComponentPointsWhy
Journal tier 10 / 10 Tier 1 — top-tier general journal (JAMA)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 11 / 12 A large phase 3 trial
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2023 — within 6 year(s) of the newest study here
Sample size 3 / 4 1,736 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 1 / 2 Randomized (as stated in the record)
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 37459141)
Free to read — / 2 Access not recorded — left out of this score
Points 48 / 62 Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 48 of the 62 points we could judge it on is 77 out of 100.
Total 77 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.

In the news

1 news article on alzhub's news page cites this paper.

Later studies that cite this one

271 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Clinical trials from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Clinical trials

See all studies in Clinical trials →